Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas.

Transplantation and cellular therapy·2026

Same author

Daratumumab therapy for refractory immune cytopenias after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026

Same author

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026

Same author

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Transplantation and cellular therapy·2026

Same author

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Blood cancer journal·2026

Search research articles

相关实验视频

Updated: Jul 8, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

优化高剂量梅尔法兰的优化

Gunjan Shah¹, Sergio Giralt¹, Parastoo Dahi¹

¹Adult BMT Service Memorial Sloan Kettering Cancer Center, 530 East 74th Street, New York, NY 10021, United States of America.

|December 14, 2023

概括

高剂量梅尔法兰 (HDM) 是多发性骨髓瘤HCT的关键. 研究了提高HDM有效性和减少骨髓抑制和粘膜炎等毒性,以获得更好的患者结果的策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

高剂量梅尔法兰 (HDM) 是多发性骨髓瘤中自主造血细胞移植 (HCT) 调节方案的基石.
尽管有效,但HDM与显著的毒性有关,包括骨髓抑制,胃肠道问题和粘膜炎.

研究的目的:

审查当前提高多发性骨髓瘤治疗中HDM疗效的策略.
探索在接受HCT的患者中减轻HDM相关毒性的方法.

主要方法:

审查已建立和新兴的方法来管理HDM毒性,如剂量修改,抗药,冷疗法,阿米福斯和生长因子.
讨论新的策略,包括个性化剂量,组合疗法 (例如,与busulfan,bendamustine),以及新的配方,如无烯糖醇的melphalan (Evomela).

主要成果:

已建立的方法有效地管理常见的HDM毒性.
个性化剂量,组合疗法和新型配方显示出优化梅尔法兰暴露和减少不良影响的前景.

结论:

有多种策略可以改善多发性骨髓瘤中HDM的治疗指数.
需要进一步的临床试验来验证这些策略,旨在提高安全性和疗效,以改善患者的治疗结果.

关键词:

自主干细胞移植自主干细胞移植高剂量治疗疗法高剂量治疗梅尔法兰是什么意思骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

相关实验视频

Last Updated: Jul 8, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025